

# Deborah M Stephens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2006647/publications.pdf>

Version: 2024-02-01

97  
papers

2,829  
citations

257450

24  
h-index

182427

51  
g-index

97  
all docs

97  
docs citations

97  
times ranked

3500  
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	1.4	50
2	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. <i>Blood</i> , 2022, 139, 1794-1806.	1.4	66
3	Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e435-e442.	0.4	6
4	Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients. <i>Blood</i> , 2022, 140, 401-405.	1.4	6
5	Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. <i>Clinical Cancer Research</i> , 2022, 28, 3242-3247.	7.0	14
6	NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 622-634.	4.9	33
7	Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 46-52.	1.2	28
8	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. <i>Leukemia</i> , 2021, 35, 3201-3211.	7.2	25
9	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. <i>Clinical Cancer Research</i> , 2021, 27, 4814-4824.	7.0	23
10	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 3327-3338.	1.4	47
11	Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01414.	1.6	1
12	Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. <i>Blood</i> , 2021, 138, 1099-1109.	1.4	14
13	Optimal Frontline Therapy for Young or Fit Patients with Chronic Lymphocytic Leukemia: A Case-Based Discussion. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S45-S48.	0.4	0
14	Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. <i>Haematologica</i> , 2021, 106, 2845-2852.	3.5	18
15	Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 884-884.	1.4	7
16	Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States. <i>Blood</i> , 2021, 138, 1930-1930.	1.4	0
17	Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States. <i>Blood</i> , 2021, 138, 1973-1973.	1.4	3
18	Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry. <i>Blood</i> , 2021, 138, 2637-2637.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Safety and Efficacy of Ibrutinib Maintenance (I-M) Following Frontline Induction in Mantle Cell Lymphoma (MCL) with Sequential Assessment of Changes in NGS-MRD. <i>Blood</i> , 2021, 138, 3530-3530.	1.4	0
20	Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>Blood</i> , 2021, 138, 165-165.	1.4	6
21	Extranodal Presentation in Limited Stage DLBCL As a Prognostic Marker in Three Sequential SWOG Trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592). <i>Blood</i> , 2021, 138, 1423-1423.	1.4	2
22	Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. <i>Blood</i> , 2021, 138, 532-532.	1.4	1
23	Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study. <i>Blood</i> , 2021, 138, 392-392.	1.4	15
24	Treatment Outcomes of Consolidative Radiation in Extranodal Early-Stage Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 49-49.	1.4	1
25	Investigating the Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy: Results from a Phase Ib Study. <i>Blood</i> , 2021, 138, 2631-2631.	1.4	2
26	Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study. <i>Blood</i> , 2021, 138, 529-529.	1.4	4
27	Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG) Tj ETQq1 10.784314 rgBT /O	1.4	1
28	Is there a role for anti-CD20 antibodies in CLL?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 68-75.	2.5	2
29	Positron Emission Tomographyâ€Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	1.6	75
30	Next-Generation Bruton Tyrosine Kinase Inhibitors. <i>Journal of Clinical Oncology</i> , 2020, 38, 2937-2940.	1.6	2
31	Burkitt Lymphoma Presenting as Cranial Multineuritis Secondary to Primary Neurolymphomatosis: A Diagnostic Challenge. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e201-e204.	0.4	0
32	A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study. <i>Leukemia Research</i> , 2020, 89, 106302.	0.8	5
33	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , 2020, 135, 1204-1213.	1.4	130
34	Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients. <i>Blood</i> , 2020, 136, 40-41.	1.4	26
35	Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2020, 136, 39-40.	1.4	40
36	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 185-217.	4.9	40

#	ARTICLE	IF	CITATIONS
37	Debate: What Is Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 993-997.	4.9	1
38	Reply: Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient?. Journal of Nuclear Medicine, 2020, 61, 1695-1695.	5.0	0
39	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood, 2019, 134, 1238-1246.	1.4	86
40	Highs and lows of minimal residual disease in CLL. Blood, 2019, 133, 386-388.	1.4	3
41	NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 12-20.	4.9	52
42	Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. British Journal of Haematology, 2019, 186, 255-262.	2.5	17
43	Cutaneous mantle cell lymphoma histomorphologically mimicking subcutaneous panniculitis-like T-cell lymphoma: Case report. Journal of Cutaneous Pathology, 2019, 46, 538-541.	1.3	4
44	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Advances, 2019, 3, 1553-1562.	5.2	145
45	Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia. Blood, 2019, 134, 1691-1696.	1.4	5
46	Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 16, 217-225.	3.3	14
47	How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood, 2019, 133, 1298-1307.	1.4	108
48	PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. Blood, 2019, 134, 349-349.	1.4	13
49	Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study. Blood, 2019, 134, 4310-4310.	1.4	4
50	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT). Blood, 2019, 134, 4286-4286.	1.4	3
51	Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis. Blood, 2019, 134, 780-780.	1.4	7
52	A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia. Blood, 2019, 134, 3049-3049.	1.4	2
53	Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation. Blood, 2019, 134, 3990-3990.	1.4	1
54	Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies. Blood, 2019, 134, 4298-4298.	1.4	58

#	ARTICLE	IF	CITATIONS
55	Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib. <i>Blood</i> , 2019, 134, 503-503.	1.4	24
56	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study. <i>Blood</i> , 2019, 134, 3039-3039.	1.4	1
57	Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis. <i>Blood</i> , 2019, 134, 3982-3982.	1.4	0
58	North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1553-1553.	1.4	0
59	A single-institution retrospective cohort study of first-line EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. <i>British Journal of Haematology</i> , 2018, 180, 259-266.	2.5	53
60	Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 534-542.	2.3	14
61	Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study. <i>Blood</i> , 2018, 132, 692-692.	1.4	17
62	Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach. <i>Blood</i> , 2018, 132, 929-929.	1.4	6
63	A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2018, 132, 3136-3136.	1.4	5
64	Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States. <i>Blood</i> , 2018, 132, 4414-4414.	1.4	1
65	Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration. <i>Blood</i> , 2018, 132, 1648-1648.	1.4	0
66	Drug-Free Macromolecular Therapeutics Induce Apoptosis in Cells Isolated from Patients with B Cell Malignancies with Enhanced Apoptosis Induction By Pretreatment with Gemcitabine. <i>Blood</i> , 2018, 132, 4426-4426.	1.4	1
67	MTHFR C677T polymorphism is associated with methotrexate-induced myelopathy risk. <i>Neurology</i> , 2017, 88, 603-604.	1.1	7
68	What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 12.	3.0	11
69	PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. <i>Blood</i> , 2017, 130, 221-228.	1.4	214
70	Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH. <i>British Journal of Haematology</i> , 2017, 179, 739-747.	2.5	101
71	Brentuximab: is it time for a new era in ABVD?. <i>Blood</i> , 2017, 130, 1281-1282.	1.4	4
72	Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1414-1427.	4.9	24

#	ARTICLE	IF	CITATIONS
73	Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. <i>Journal of Clinical Oncology</i> , 2016, 34, 2997-3004.	1.6	97
74	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 323-332.	27.0	785
75	Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 1163-1163.	1.4	7
76	Acalabrutinib Monotherapy in Patients with Ibrutinib Intolerance: Results from the Phase 1/2 ACE-CL-001 Clinical Study. <i>Blood</i> , 2016, 128, 638-638.	1.4	23
77	Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells. <i>Oncotarget</i> , 2016, 7, 12806-12822.	1.8	10
78	BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma. <i>Blood</i> , 2016, 128, 2767-2767.	1.4	0
79	Risk-Stratified Treatment in Chronic Lymphocytic Leukemia. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 314-317.	0.4	0
80	Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation. <i>Oncology</i> , 2016, 30, 970-4, 980-1, C3.	0.5	19
81	Jumping translocations, a novel finding in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 200-207.	2.5	8
82	Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2015, 90, 967-969.	4.1	2
83	Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 242-252.	2.5	26
84	Subcutaneous Injections of IMMU-114 (Anti-HLA-DR IgG4 Monoclonal Antibody): Initial Results of a Phase I First-in-Man Study in Hematologic Malignancies. <i>Blood</i> , 2015, 126, 2740-2740.	1.4	8
85	A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2951-2951.	1.4	10
86	The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile. <i>Blood</i> , 2015, 126, 831-831.	1.4	0
87	Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. <i>MAbs</i> , 2014, 6, 748-754.	5.2	37
88	Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. <i>Leukemia</i> , 2014, 28, 1365-1368.	7.2	19
89	BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 4681-4681.	1.4	2
90	Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2013, 37, 1195-1199.	0.8	26

#	ARTICLE	IF	CITATIONS
91	Improving the Treatment Outcome of Patients with Chronic Lymphocytic Leukemia Through Targeted Antibody Therapy. Hematology/Oncology Clinics of North America, 2013, 27, 303-327.	2.2	9
92	Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype. Blood, 2013, 122, 2872-2872.	1.4	0
93	Externally Validated Predictive Clinical Model For Untreated Del(17p13.1) Chronic Lymphocytic Leukemia Patients. Blood, 2013, 122, 4128-4128.	1.4	0
94	Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica, 2012, 97, 423-427.	3.5	17
95	Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT. Bone Marrow Transplantation, 2011, 46, 84-89.	2.4	23
96	Granulocyte stimulating-colony factor-associated splenic artery rupture. Leukemia and Lymphoma, 2010, 51, 335-337.	1.3	1
97	Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients. Blood, 2010, 116, 1378-1378.	1.4	0